<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>infection on Russell E. Lewis</title>
    <link>https://russlewisid.com/categories/infection/</link>
    <description>Recent content in infection on Russell E. Lewis</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en</language>
    <lastBuildDate>Thu, 20 May 2021 00:00:00 +0000</lastBuildDate><atom:link href="https://russlewisid.com/categories/infection/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies-is there an excess risk for infection?</title>
      <link>https://russlewisid.com/blog/evergreen/</link>
      <pubDate>Thu, 20 May 2021 00:00:00 +0000</pubDate>
      
      <guid>https://russlewisid.com/blog/evergreen/</guid>
      <description>Gudiol C, Lewis RE, Strati P, Kontoyiannis DP. Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection? Lancet Haematol 2021; 8:e216â€“e228. Available at: http://dx.doi.org/10.1016/S2352-3026(20)30376-8.
Abstract Therapy with genetically engineered chimeric antigen receptor (CAR) T cells targeting the CD19 antigen is promising for a number of refractory or relapsed B-cell malignancies. Information on the infectious complications of this immunotherapeutic strategy is scarce and difficult to interpret, as many factors influence infection incidence and outcomes.</description>
    </item>
    
  </channel>
</rss>
